Valuation: Tarsus Pharmaceuticals, Inc.

Market Cap 2.77B 2.43B 2.24B 2.09B 3.93B 261B 4B 26.88B 10.41B 129B 10.4B 10.17B 447B P/E 2026 *
-101x
P/E 2027 * 20.6x
Enterprise Value 2.77B 2.43B 2.24B 2.09B 3.93B 261B 4B 26.88B 10.41B 129B 10.4B 10.17B 447B EV / Sales 2026 *
3.98x
EV / Sales 2027 * 3.06x
Free-Float
96.91%
Yield 2026 *
-
Yield 2027 * -
1 day-4.13%
1 week+1.87%
Current month+8.32%
1 month+3.34%
3 months-3.91%
6 months-22.02%
Current year-21.42%
1 week 62.51
Extreme 62.51
69.48
1 month 56
Extreme 56
69.48
Current year 56
Extreme 56
83.92
1 year 38.51
Extreme 38.51
85.25
3 years 12.57
Extreme 12.57
85.25
5 years 10.8
Extreme 10.8001
85.25
10 years 10.8
Extreme 10.8001
85.25
Manager TitleAgeSince
Chief Executive Officer 48 31/08/2018
Director of Finance/CFO 64 23/04/2023
Chief Operating Officer 57 15/07/2020
Director TitleAgeSince
Chairman 48 01/12/2022
Director/Board Member 71 30/11/2019
Director/Board Member 80 31/12/2016
Date Insider Type Main position Quantity % Market Cap.
06-16Sell

Chief Executive Officer

-10,000 0.0232%
06-15Sell

Chief Financial Officer

-14,396 0.0335%
06-14Sell

Director

-12,500 0.0291%
Change 5-day change 1-year change 3-year change Capi.($)
-4.13%+1.87%+60.05%+252.55% 2.77B
-0.53%+1.67%+19.19%-20.47% 63.09B
+0.63%+2.97%+51.92%+206.64% 55.61B
+0.07%+38.60%+38.60%+38.60% 41.64B
-2.02%-0.90%-51.97%-58.83% 38.98B
+1.19%+2.74%+58.64%-29.02% 29.82B
-1.11%-6.58%+122.45%-49.58% 23.71B
-0.86%+9.48%+59.19%+72.19% 21.48B
-1.97%-1.13%-5.22%+140.32% 16.87B
-0.25%+6.77%+69.55%+122.96% 16.74B
Average -0.91%+2.87%+42.24%+67.54% 31.07B
Weighted average by Cap. -0.43%+2.90%+34.90%+45.54%

Financials

2026 *2027 *
Net sales 696M 612M 564M 527M 988M 65.71B 1.01B 6.76B 2.62B 32.39B 2.62B 2.56B 113B 905M 795M 732M 684M 1.28B 85.35B 1.31B 8.78B 3.4B 42.07B 3.4B 3.32B 146B
Net income -28.48M -25.01M -23.05M -21.55M -40.42M -2.69B -41.16M -277M -107M -1.32B -107M -105M -4.6B 158M 139M 128M 120M 224M 14.9B 228M 1.53B 594M 7.35B 593M 580M 25.53B
Net Debt - -
Logo Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics, starting with eye care. The Company’s lead product candidate, XDEMVY, is a lotilaner ophthalmic solution that targets and eradicates the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API) of XDEMVY, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride channels. The Company is investigating the development of its product candidates to address targeted diseases with high unmet medical needs, which include TP-04, a novel ophthalmic gel formulation of lotilaner for the potential treatment of Ocular Rosacea, and TP-05, a novel investigational oral formulation of lotilaner, for potential Lyme disease prophylaxis and community malaria reduction.
Employees
370
Date Price Change Volume
25/06/26 US$64.34 -4.13% 510,853
24/06/26 US$67.11 +1.42% 910,160
23/06/26 US$66.17 +4.11% 1,289,789
22/06/26 US$63.56 +0.63% 788,703
18/06/26 US$63.16 +0.98% 402,143
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
64.34USD
Average target price
94.11USD
Spread / Average Target
+46.27%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TARS Stock